Novo prevents Teva’s Victoza rival launch until 2023Novo Nordisk has settled a US patent case with Teva, which prevents the Israel-based generics firm marketing a Share XNovo prevents Teva’s Victoza rival launch until 2023https://pharmaphorum.com/news/novo-prevents-tevas-victoza-rival-launch-until-2023/
Q4 results roundup 2019With the full year results season drawing to a close, Richard Staines asks who the winners were and Share XQ4 results roundup 2019https://pharmaphorum.com/sales-marketing/q4-results-roundup-2019/
Teva’s migraine drug Ajovy looks set for EU approvalTeva’s migraine drug Ajovy (fremanezumab) has moved closer to the EU market after the influential CHMP regulatory committee Share XTeva’s migraine drug Ajovy looks set for EU approvalhttps://pharmaphorum.com/news/tevas-migraine-drug-ajovy-looks-set-for-eu-approval/
CVS covers migraine drugs from Teva and Lilly, excludes Amgen’s rivalUS pharmacy benefits manager CVS Health Corp has added new migraine drugs from Teva and Eli Lilly to Share XCVS covers migraine drugs from Teva and Lilly, excludes Amgen’s rivalhttps://pharmaphorum.com/news/cvs-covers-migraine-drugs-from-teva-and-lilly-excludes-amgens-rival/
Teva and Neos settle over Cotempla patent disputeTeva and Neos Therapeutics have reached a confidential settlement and licensing agreement that resolves a patent dispute over Share XTeva and Neos settle over Cotempla patent disputehttps://pharmaphorum.com/news/teva-and-neos-settle-over-cotempla-patent-dispute/
Celltrion/Teva’s Herceptin biosimilar approved in USThe FDA has approved Celltrion and Teva’s biosimilar of Roche’s breast cancer drug Herceptin, the second potential competitor Share XCelltrion/Teva’s Herceptin biosimilar approved in UShttps://pharmaphorum.com/news/celltrion-tevas-herceptin-biosimilar-approved-in-us/
Lilly files new class migraine drug with FDAEli Lilly has filed a new migraine drug, lasmiditan, with the US regulator, the first drug in its Share XLilly files new class migraine drug with FDAhttps://pharmaphorum.com/news/lilly-files-new-class-migraine-drug-with-fda/
Sandoz axes filing of US Rituxan biosimilarSandoz has abandoned plans to get a cheaper biosimilar of Swiss rival Roche’s cancer drug Rituxan (rituximab) approved Share XSandoz axes filing of US Rituxan biosimilarhttps://pharmaphorum.com/news/sandoz-axes-filing-of-us-rituxan-biosimilar/
Teva slumps after Express Scripts funds migraine rivals in USA major prescription benefit manager in the US will not reimburse Teva’s preventative migraine drug Ajovy (fremanezumab), in Share XTeva slumps after Express Scripts funds migraine rivals in UShttps://pharmaphorum.com/news/teva-slumps-after-express-scripts-funds-migraine-rivals-in-us/
